Related references
Note: Only part of the references are listed.Identification of preexisting adaptive immunity to Cas9 proteins in humans
Carsten T. Charlesworth et al.
NATURE MEDICINE (2019)
A New Class of Medicines through DNA Editing
Matthew H. Porteus
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
Shayesteh R. Ferdosi et al.
NATURE COMMUNICATIONS (2019)
Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function
Kilian Schober et al.
NATURE BIOMEDICAL ENGINEERING (2019)
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Lei Xu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S. Nowicki et al.
CLINICAL CANCER RESEARCH (2019)
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Dimitrios L. Wagner et al.
NATURE MEDICINE (2019)
CRISPR-Cas9 genome engineering of primary CD4(+) T cells for the interrogation of HIV-host factor interactions
Judd F. Hultquist et al.
NATURE PROTOCOLS (2019)
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
Christopher L. Nobles et al.
GENOME BIOLOGY (2019)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
Vijaya L. Simhadri et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements (vol 36, pg 765, 2018)
Michael Kosicki et al.
NATURE BIOTECHNOLOGY (2018)
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
Christopher A. Vakulskas et al.
NATURE MEDICINE (2018)
CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells
Xiaojuan Liu et al.
CELL RESEARCH (2017)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June et al.
NATURE MEDICINE (2017)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
A versatile system for rapid multiplex genome-edited CAR T cell generation
Jiangtao Ren et al.
ONCOTARGET (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
Rasmus O Bak et al.
eLife (2017)
Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
Inna Serganova et al.
MOLECULAR THERAPY-ONCOLYTICS (2017)
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2016)
TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
Laurie Menger et al.
CANCER RESEARCH (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Shu Su et al.
SCIENTIFIC REPORTS (2016)
Multiplex Genome-Edited T-cell Manufacturing Platform for Off-the-Shelf Adoptive T-cell Immunotherapies
Laurent Poirot et al.
CANCER RESEARCH (2015)
Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells
Pamela M. Odorizzi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Aaron P. Rapoport et al.
NATURE MEDICINE (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Shengdar Q. Tsai et al.
NATURE BIOTECHNOLOGY (2015)
Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR/Cas9
Pankaj K. Mandal et al.
CELL STEM CELL (2014)
Incidence of bcr-abl fusion transcripts in healthy individuals
Said I. Ismail et al.
MOLECULAR MEDICINE REPORTS (2014)
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Danilo Maddalo et al.
NATURE (2014)
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Pablo Tebas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong et al.
SCIENCE (2013)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Elena Provasi et al.
NATURE MEDICINE (2012)
Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State
Andrea Schietinger et al.
SCIENCE (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Persistence of space radiation induced cytogenetic damage in the blood lymphocytes of astronauts
K. George et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2010)
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Gavin M. Bendle et al.
NATURE MEDICINE (2010)
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines
Yangbing Zhao et al.
JOURNAL OF IMMUNOLOGY (2007)
Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tunior cell lines
YB Zhao et al.
JOURNAL OF IMMUNOLOGY (2005)
Endogenous DNA double-strand breaks: Production, fidelity of repair, and induction of cancer
MM Vilenchik et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Leukemia- and lymphoma-associated genetic aberrations in healthy individuals
J Bäsecke et al.
ANNALS OF HEMATOLOGY (2002)
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution
S Bownds et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Share Paper
